Decision-Ready Insights For Drug Development Teams
Capture the regulatory insights that matter, before you have to look for them.
A team of specialized AI agents assessing the signals that impact your development program and pipeline, from regulatory expectations and precedents to clinical readouts, and competitive pressure.
SemaglutideObesity · GLP-1 · Approved
- Context
- History
- Landscape
- Strategy
- Assumptions
- Insights
DetectedFDA · 15 Aug 2025
On 15 August 2025 FDA granted accelerated approval for Wegovy (semaglutide) injection in adults with noncirrhotic MASH and moderate to advanced liver fibrosis. FDA specifies fibrosis stages F2–F3.
What it means for the teamFDA added the MASH indication under accelerated approval in August 2025. Continued approval depends on confirmation of clinical benefit.
How the specialized agents work
Your agents watch, assess, and brief, before anyone asks.
Specialized Cedience agents run the intelligence layer autonomously. They watch public drug-development records that general agents cannot fully see, assess a relevant event against the program state they already hold, and deliver one cited brief, through login to the Cedience platform and through a connection into the internal agents or platform you use.
- Detect
Regulatory · Strategy · Labeling · Clinical · Pharmacology · Market access · Competitive
- Assess
History · Landscape · Strategy · Assumptions
- Report
Login · Access the Cedience platform; Connect · Your intelligence toolbox (ex: internal dashboard, tools, or third-party solutions), Your enterprise conversational AI agent via MCP (ex: Claude, Copilot, Gemini...), Your team's communication channels (ex: MS Teams, Slack...)
How the signal is assessed
Semaglutide's MASH approval raises the bar for survodutide.
- What it means
- In August 2025 the FDA granted semaglutide accelerated approval for noncirrhotic MASH with moderate to advanced fibrosis, the first GLP-1 approved in the indication, on histologic endpoints with confirmatory cirrhosis-free-survival evidence due in 2029. A same-class mechanism clearing that surrogate-endpoint pathway confirms the route survodutide's program is built around, and the confirmatory obligation that comes with it.
- For this program
- Survodutide is a GLP-1 and glucagon receptor agonist in two Phase 3 MASH trials: LIVERAGE in noncirrhotic F2 to F3 disease and LIVERAGE-Cirrhosis in compensated cirrhosis, with estimated primary completion in 2031 and 2029. It holds FDA Breakthrough Therapy Designation in noncirrhotic MASH. Semaglutide's approval, alongside resmetirom, means survodutide would enter a market with two established drugs, while its glucagon component and its direct cirrhosis trial reach efficacy and a population neither approved drug is labeled for.
High
Regulatory · High
A same-class GLP-1 cleared the FDA's surrogate-endpoint MASH pathway. It confirms the accelerated route, and the confirmatory obligation attached to it, that survodutide's LIVERAGE program is built around.
What powers the intelligence layer
The engine driving the insights.
- 1.4B
- Datapoints
- 40M
- Records
- 75
- Sources
- 120K
- Products
- 60
- Agencies
- 53
- Agents
Decision-Ready Insights